A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Inclusion Criteria: * Male or female, 18 years of age or older. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of ≤ 20% (well and moderately differentiated) * Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent. * Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted. * Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12 months prior basal visit. * Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy. * Patient has to be able to swallow the medication. * Life expectancy greater than 12 weeks. * The definitions of minimum adequacy for organ function required prior to study entry are as follows: * Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy * Total serum bilirubin ≤ 1.5 x ULN * Serum albumin ≥ 3.0 g/dL * Absolute neutrophil count (ANC) ≥ 1500/µL * Platelets ≥ 100,000/µL * Hemoglobin ≥ 5,6 mmol/L (9.0 g/dL) * Creatinin …